You are here: Industry Insights > Keytruda

News List

NHS England makes Keytruda available for advanced colorectal cancer during pandemic pharmatimes
March 29, 2021
NHS England has reached an interim treatment agreement with MSD for Keytruda for the treatment of certain advanced colorectal cancer patients during the COVID-19 pandemic.
FDA casts doubt on clinical meaningfulness of Merck’s Keytruda trial data pharmaceutical-technology
February 09, 2021
The US Food and Drug Administration (FDA) has cast doubt on the results from Merck’s KEYNOTE-522 trial of Keytruda (pembrolizumab) submitted to support its expanded label in treating triple-negative breast cancer (TNBC).
Keytruda recommended for routine NHS use in lung cancer pharmatimes
February 05, 2021
MSD’s immunotherapy Keytruda (pembrolizumab) has gained a NICE recommendation for NHS England routine commissioning for the first-line treatment of non-small cell lung cancer (NSCLC).
Keytruda scores new EU approval in colorectal cancer pharmatimes
January 27, 2021
MSD’s immunotherapy Keytruda (pembrolizumab) has been approved in the EU for the first-line treatment of metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal cancer.
Inhibrx Announces Phase 1 Dose Escalation Results of Novel Hexavalent OX40 Agonist americanpharmaceuticalreview
January 13, 2021
Inhibrx has announced results from Part 1 of the Phase 1 dose escalation trial of INBRX-106, a novel hexavalent OX40 agonist, in development for the treatment of solid tumors.
FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer pharmaceutical-business-review
December 22, 2020
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and ...
Merck reports positive results for Keytruda, Lenvima combo in phase 3 KEYNOTE-775/Study 309 trial pharmaceutical-business-review
December 21, 2020
Merck and Eisai announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai ..
Triple combination of therapies shows promise in pancreatic cancer trial europeanpharmaceuticalreview
December 18, 2020
The combination of motixafortide, KEYTRUDA® and chemotherapy met all trial endpoints, including increasing overall and progression free survival.
FDA approves Merck’s Keytruda with chemotherapy to treat breast cancer pharmaceutical-technology
November 17, 2020
Merck (MSD) has secured approval from the US Food and Drug Administration (FDA) for its Keytruda in combination with chemotherapy for treating patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumours ..
Lenvima plus Keytruda achieves primary endpoints in trial for RCC europeanpharmaceuticalreview
November 12, 2020
Lenvima and Keytruda has demonstrated positive top-line results in a Phase III trial in patients with advanced renal cell carcinoma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page